Author + information
- Received October 16, 2016
- Accepted October 20, 2016
- Published online January 16, 2017.
- Hiroki Shiomi, MDa,
- Takeshi Morimoto, MD, PhDb,
- Shoji Kitaguchi, MDc,
- Yoshihisa Nakagawa, MDd,
- Katsuhisa Ishii, MDe,
- Yoshisumi Haruna, MD, PhDc,
- Itaru Takamisawa, MDf,
- Makoto Motooka, MDg,
- Kazuhiro Nakao, MDh,
- Shintaro Matsuda, MDi,
- Satoru Mimoto, MDj,
- Yutaka Aoyama, MDk,
- Teruki Takeda, MDl,
- Koichiro Murata, MDm,
- Masaharu Akao, MDn,
- Tsukasa Inada, MDo,
- Hiroshi Eizawa, MDi,
- Eiji Hyakuna, MDp,
- Kojiro Awano, MDq,
- Manabu Shirotani, MDr,
- Yutaka Furukawa, MDs,
- Kazushige Kadota, MDt,
- Katsumi Miyauchi, MDu,
- Masaru Tanaka, MDo,
- Yuichi Noguchi, MDv,
- Sunao Nakamura, MDj,
- Satoshi Yasuda, MDh,
- Shunichi Miyazaki, MDw,
- Hiroyuki Daida, MDu,
- Kazuo Kimura, MDx,
- Yuji Ikari, MDy,
- Haruo Hirayama, MD, PhDk,
- Tetsuya Sumiyoshi, MDf,
- Takeshi Kimura, MDa,∗ (, )
- ReACT Investigators
- aDepartment of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Japan
- bDepartment of Clinical Epidemiology, Hyogo College of Medicine, Hyogo, Japan
- cDivision of Cardiology, Hirakata Kohsai Hospital, Hirakata, Japan
- dDivision of Cardiology, Tenri Hospital, Nara, Japan
- eDivision of Cardiology, Kansai Electric Power Hospital, Osaka, Japan
- fDepartment of Cardiology, Sakakibara Heart Institute, Japan Research Promotion Society for Cardiovascular Diseases, Tokyo, Japan
- gDivision of Cardiology, Shizuoka General Hospital, Shizuoka, Japan
- hDepartment of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Osaka, Japan
- iDivision of Cardiology, Nishikobe Medical Center, Kobe, Japan
- jDepartment of Cardiology, New Tokyo Hospital, Tokyo, Japan
- kDepartment of Cardiology, Nagoya Second Red Cross Hospital, Nagoya, Japan
- lDivision of Cardiology, Koto Memorial Hospital, Higashioumi, Japan
- mDepartment of Cardiology, Shizuoka City Shizuoka Hospital, Shizuoka, Japan
- nDepartment of Cardiology, National Hospital Organization Kyoto Medical Center, Kyoto, Japan
- oCardiovascular Center Osaka Red Cross Hospital, Osaka, Japan
- pDepartment of Cardiology, Saiseikai Shimonoseki General Hospital, Yamaguchi, Japan
- qDepartment of Cardiology, Kitaharima Medical Center, Hyogo, Japan
- rDepartment of Cardiology, Kindai University Nara Hospital, Nara, Japan
- sDepartment of Cardiovascular Medicine, Kobe City Medical Center General Hospital, Kobe, Japan
- tDivision of Cardiology, Kurashiki Central Hospital, Kurashiki, Japan
- uDepartment of Cardiovascular Medicine, Juntendo University, Graduate School of Medicine, Tokyo, Japan
- vDepartment of Cardiology, Tsukuba Medical Center Hospital, Tsukuba, Japan
- wDivision of Cardiology, Kindai University, Osaka, Japan
- xDivision of Cardiology, Yokohama City University Medical Center, Yokohama, Japan
- yDepartment of Cardiology, Tokai University, Kanagawa, Japan
- ↵∗Reprint requests and correspondence:
Dr. Takeshi Kimura, Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan.
Objectives The purpose of this study was to evaluate long-term clinical impact of routine follow-up coronary angiography (FUCAG) after percutaneous coronary intervention (PCI) in daily clinical practice in Japan.
Background The long-term clinical impact of routine FUCAG after PCI in real-world clinical practice has not been evaluated adequately.
Methods In this prospective, multicenter, open-label, randomized trial, patients who underwent successful PCI were randomly assigned to routine angiographic follow-up (AF) group, in which patients were to receive FUCAG at 8 to 12 months after PCI, or clinical follow-up alone (CF) group. The primary endpoint was defined as a composite of death, myocardial infarction, stroke, emergency hospitalization for acute coronary syndrome, or hospitalization for heart failure over a minimum of 1.5 years follow-up.
Results Between May 2010 and July 2014, 700 patients were enrolled in the trial among 22 participating centers and were randomly assigned to the AF group (n = 349) or the CF group (n = 351). During a median of 4.6 years of follow-up (interquartile range [IQR]: 3.1 to 5.2 years), the cumulative 5-year incidence of the primary endpoint was 22.4% in the AF group and 24.7% in the CF group (hazard ratio: 0.94; 95% confidence interval: 0.67 to 1.31; p = 0.70). Any coronary revascularization within the first year was more frequently performed in AF group than in CF group (12.8% vs. 3.8%; log-rank p < 0.001), although the difference between the 2 groups attenuated over time with a similar cumulative 5-year incidence (19.6% vs. 18.1%; log-rank p = 0.92).
Conclusions No clinical benefits were observed for routine FUCAG after PCI and early coronary revascularization rates were increased within routine FUCAG strategy in the current trial. (Randomized Evaluation of Routine Follow-up Coronary Angiography After Percutaneous Coronary Intervention Trial [ReACT]; NCT01123291)
Supported by an educational grant from the Research Institute for Production Development (Kyoto, Japan).
Dr. Morimoto received honoraria for education consulting from Boston Scientific Corporation. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
- Received October 16, 2016.
- Accepted October 20, 2016.
- American College of Cardiology Foundation